The Innovative Health Initiative (IHI)


Got questions? Find answers to commonly asked questions about IHI.

Why is the EU going from IMI to IHI?

IHI builds on what worked well in IMI, addresses the lessons learnt, and leverages the benefits of cross-sectoral collaboration in research and innovation to better respond to current and emerging health needs.

Its number one goal is to translate health research and innovation into tangible benefits for patients and societies.

In practice, all of this means that while some elements will stay the same, others change significantly.

As in IMI, the EU will provide 50 % of the funding for IHI, and the industry members will contribute the other 50%, primarily through ‘in-kind’ contributions. The total budget is 2.4 billion euros.

Which industry partners are involved in IHI?

As was the case in IMI, the ‘public’ member in the partnership is the European Union, represented by the European Commission.

The industry members are COCIREFPIA (including Vaccines Europe), EuropaBio and MedTech Europe, taking IHI beyond the pharmaceutical industry and bringing on board the medical technology, biotechnology, digital health and vaccine industries.

In addition, organizations that want to support specific research areas without becoming full members of IHI can apply to become ‘contributing partners’ (similar to the Associated Partners in IMI2).

Will IHI be governed differently from IMI?

New under IHI is the Science and Innovation Panel (S&IP), an advisory body that will bring together representatives of the scientific community and the wider health sector, such as regulatory bodies, patients and end-users. The panel will also include representatives of the European Commission and the industry partners of IHI and SRG members. The panel may also invite additional ad-hoc experts to join in discussions of specific subjects.

Like IMI, IHI has a Governing Board composed of equal numbers of representatives from the European Commission and the industry partners, plus a States Representatives Group (SRG) comprising representatives of the EU Member States plus countries associated with Horizon Europe.

What is the role of the new Science and Innovation Panel (S&IP)?

The S&IP will provide science-based advice to the Governing Board on scientific and technological matters such as: 

  • IHI’s draft work programmes, and in particular the draft call topics;
  • updates to the Strategic Research and Innovation Agenda (SRIA);
  • the planning of additional activities;
  • the set-up of advisory groups focused on specific scientific priorities;
  • synergies with other Horizon Europe activities, including other European partnerships and other EU and national programmes.

More about S&IP procedures, its members and meetings (IHI website)

When will IHI calls be published, and on which topics?

It is expected that IHI will launch the one and two-stage calls in mid-June 2022. 

On April 20th IHI published draft topics, which will help you to start on time to work on your proposal and look for partners. We expect the deadline for full single-stage proposals at the end of September 2022. 

Single-stage calls:

  • Innovative patient-facing care pathways for patients with neurodegenerative diseases and comorbidities
  • Next-generation imaging and image-guided diagnosis and therapy for cancer
  • Precision oncology: Innovative patient-centric, multi-modal therapies against cancer

Two-stage calls:

  • New tools for prediction, prevention and monitoring of cardio-metabolic diseases, including secondary manifestations, to enable timely intervention
  • Strengthening EU clinical development excellence and innovation attractiveness: Harmonised methodology to promote the uptake of early feasibility studies (EFS)

For more information per draft topic visit the IHI website 

Note: All information regarding future IHI Call topics is indicative and subject to change. Final information about future IHI Calls will be communicated after approval by the IHI Governing Board.

How do I write a successful proposal?

Writing a proposal and finding the right partners takes a lot of time and effort. In our brand-new Horizon Europe magazine, you will find a step-by-step roadmap, which will guide you in writing a successful IHI proposal in four phases. Our advice: start now! See the previous question for information on the draft topics in IHI.

When will a single-stage call be eligible for evaluation?

The one-stage procedure is a bottom-up approach that allows much more flexibility than the 2-stage proposals. The call text is written by IHI/Science and Innovation panel (S&IP) and not by industry partners. So, public partners and Industry write the application together from the beginning. 

Partner organizations could be academics, hospitals, public bodies, regulators NGOs, research organizations, for-profit legal entities (SME and larger enterprises), Patients’ Organizations and intergovernmental organizations. established in a member state or Associated Country. New under IHI: organizations can also be based in Low and Middle-Income Countries (see Horizon Europe list

Important: at least 45% in-kind contribution of the total project costs needs to come from the consortium. Proposals not meeting this criterion will not be considered for evaluation!

What does the single-stage procedure look like?

visual ihi faq

How many single-stage proposals will IHI fund?

Based on our current information, several proposals will be funded (in contrast with two-stage calls). However, the final number will depend on the available budget for single-stage calls.

‘Bringing researchers, entrepreneurs and stakeholders together to work on sustainable solutions in healthcare. That is what we do. And that will be the big challenge in IHI. How to find the right partners? How do you align your goals with those of others? My appeal: start on time!  We are already discussing with some of our strategic accounts how we are going to build the ideal consortium.’


Is your question not listed?

Send us a message and we will contact you to see how we can help you.